|
- 2017
Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer | Journal of Peritoneum (and other serosal surfaces)DOI: https://doi.org/10.4081/joper.2017.59 Keywords: Gynecologic cancer, gynecologic cancer, ovarian cancer, ovarian cancer, hyperthermic intraperitoneal chemotherapy, HIPEC, early postoperative intraperitoneal chemotherapy, EPIC, cytoreductive surgery, IP chemotherapy for ovarian cancer, neoadjuvant chemotherapy, cytoreductive surgery for ovarian cancer, clinical trials, NACT for ovarian cancer. Abstract: Ovarian cancer is commonly diagnosed after dissemination and is accompanied by a poorer overall prognosis. Treatment incorporates a multimodal approach, utilizing various combinations of surgery and chemotherapy. Ultimately, better screening tests are needed for ovarian cancer to help reduce the burden of advanced-stage disease. For those women with advanced-stage tumors, newer therapeutic strategies may help prolong survival and increase the chance for cure. The aim of this study is to review current trends in the treatment of women diagnosed with advanced-stage epithelial ovarian cancer
|